Matthew Gall
Equibles does not estimate personal net worth.
Get an email with a short summary when Kalaris Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get KLRS alertsAbout Matthew Gall
Matthew Gall is recorded as CFO at Kalaris Therapeutics, Inc. (KLRS) since November 3, 2025. Kalaris Therapeutics, Inc. reported in an 8-K filed April 10, 2026 that Matthew Gall resigned as Chief Financial Officer, effective April 14, 2026. Kalaris Therapeutics, Inc. reported in an 8-K filed November 3, 2025 that Matthew Gall was appointed Chief Financial Officer and Treasurer, effective November 3, 2025. The proxy statement of Kalaris Therapeutics, Inc. reports total compensation of $1,064,607 for Matthew Gall in fiscal 2025, including a base salary of $80,833. Kalaris Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Kalaris Therapeutics, Inc. includes Andrew Oxtoby (CEO and Board Member), Diana M. Brainard (CEO and Board Member), Vikas Sinha (CEO) and 7 others.
“On April 8, 2026, Matthew Gall notified Kalaris Therapeutics, Inc. (the "Company") of his decision to resign as the Chief Financial Officer of the Company, effective April 14, 2026 (the "Separation Date").”
“On October 28, 2025, the Board of Directors (the "Board") of Kalaris Therapeutics, Inc. (the "Company") appointed Matthew Gall as Chief Financial Officer and Treasurer of the Company, effective as of November 3, 2025 (the "Effective Date").”
Affiliation history
-
Current
2025-11-03–present
-
2025-11-03–2026-04-14
-
Start not stated–2026-04-14
Company network
Leadership on record at Kalaris Therapeutics, Inc.
- Andrew Oxtoby CEO, Board Member
- Diana M. Brainard CEO, Board Member
- Vikas Sinha CEO
- David Hallal Chairman, Board Member
- Brett Hagen CFO
- Liisa Bayko CFO
- Amy Vandekop Chief Accounting Officer
- Anthony Adamis Board Member
- Derek Adams, Ph.D. Board Member
- Laurie Keating Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Kalaris Therapeutics, Inc. (KLRS) | Former Chief Financial Officer | $80,833 | $1,064,607 |